
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities

Over 240 million people worldwide live with chronic hepatitis B

The new three-year agreement builds on an existing two-year relationship

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

RSV affects approximately 64 million people around the world each year

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

Approval supported by positive results from phase 3 trial

The deal includes a PDE3/4 inhibitor in clinical development for COPD

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

The decision means that eligible patients in England will be the first in the world to access the combination

Steatotic liver disease affects approximately 5% of the global population